Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study

PURPOSE: The aim was to compare outcomes in adult patients with inflammatory bowel disease (IBD) who switched to infliximab-dyyb with those who remained on reference product (RP) infliximab in the United States (US) in a retrospective, propensity score-matched, non-inferiority cohort trial. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Stephanie L., Niu, Fang, Pola, Suresh, Velayos, Fernando S., Ning, Xian, Hui, Rita L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211187/
https://www.ncbi.nlm.nih.gov/pubmed/32103457
http://dx.doi.org/10.1007/s40259-020-00409-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211187/
https://www.ncbi.nlm.nih.gov/pubmed/32103457
http://dx.doi.org/10.1007/s40259-020-00409-y

Ejemplares similares